PURPOSE: The successful labelling of bisphosphonates (BP) with 68Ga using macrocyclic chelators such as the based triazacyclononane (NO2AP) is a step forward in the in-house availability of a novel bone-seeking PET radiopharmaceutical with dual advantage of PET/CT imaging and generator production. In this study, we compared the novel generator-based skeletal radiotracer 68Ga-1,4,7-triazacyclonone-1,4-diacetic acid (68Ga-NO2AP-BP) with sodium fluoride (18F-NaF) for the detection of skeletal metastases in breast cancer patients. In addition, dosimetric analysis of 68Ga-NO2AP-BP was performed in a subset of patients. METHODS: This was a prospective study of histopathologically proven cases of breast cancer patients who were referred for bone scintigraphy and underwent positron emission tomography/computed tomography (PET/CT) with 18F-NaF and 68Ga-NO2AP-BP within a week in random order. The scans of each patient were compared both qualitatively for image quality and quantitatively for number of lesions and SUVmax of lesions. Dosimetric analysis was performed in five patients. Their PET/CT scans were acquired at multiple time points and urine and blood samples were collected. Dosimetric calculations were performed using OLINDA/EXM 1.1 software. Statistical analysis was done using Stata 13 (StataCorp) software package. An agreement analysis regarding number of lesions detected with the two skeletal radiotracers was carried out. RESULTS: The image quality of 68Ga-NO2AP-BP PET/CT scans were comparable to that of 18F-NaF. There was no statistically significant difference in the SUVmax of lesions, normal bone and lesion to background ratio between the two skeletal radiotracers. There was good agreement in the number of lesions detected by both skeletal radiotracers. The mean whole body effective dose for 68Ga-NO2AP-BP was 0.00583 mSv/MBq and the effective dose equivalent was 0.0086 mSv/MBq. CONCLUSION: The excellent lesion detection agreement between 68Ga-NO2AP-BP and 18F-NaF favours the former as an alternative for skeletal scintigraphy in centres without an on-site cyclotron. The favourable dosimetric results and its potential to be used as a theranostic agent makes it an important generator-based skeletal radiotracer.
PURPOSE: The successful labelling of bisphosphonates (BP) with 68Ga using macrocyclic chelators such as the based triazacyclononane (NO2AP) is a step forward in the in-house availability of a novel bone-seeking PET radiopharmaceutical with dual advantage of PET/CT imaging and generator production. In this study, we compared the novel generator-based skeletal radiotracer 68Ga-1,4,7-triazacyclonone-1,4-diacetic acid (68Ga-NO2AP-BP) with sodium fluoride (18F-NaF) for the detection of skeletal metastases in breast cancerpatients. In addition, dosimetric analysis of 68Ga-NO2AP-BP was performed in a subset of patients. METHODS: This was a prospective study of histopathologically proven cases of breast cancerpatients who were referred for bone scintigraphy and underwent positron emission tomography/computed tomography (PET/CT) with 18F-NaF and 68Ga-NO2AP-BP within a week in random order. The scans of each patient were compared both qualitatively for image quality and quantitatively for number of lesions and SUVmax of lesions. Dosimetric analysis was performed in five patients. Their PET/CT scans were acquired at multiple time points and urine and blood samples were collected. Dosimetric calculations were performed using OLINDA/EXM 1.1 software. Statistical analysis was done using Stata 13 (StataCorp) software package. An agreement analysis regarding number of lesions detected with the two skeletal radiotracers was carried out. RESULTS: The image quality of 68Ga-NO2AP-BP PET/CT scans were comparable to that of 18F-NaF. There was no statistically significant difference in the SUVmax of lesions, normal bone and lesion to background ratio between the two skeletal radiotracers. There was good agreement in the number of lesions detected by both skeletal radiotracers. The mean whole body effective dose for 68Ga-NO2AP-BP was 0.00583 mSv/MBq and the effective dose equivalent was 0.0086 mSv/MBq. CONCLUSION: The excellent lesion detection agreement between 68Ga-NO2AP-BP and 18F-NaF favours the former as an alternative for skeletal scintigraphy in centres without an on-site cyclotron. The favourable dosimetric results and its potential to be used as a theranostic agent makes it an important generator-based skeletal radiotracer.
Entities:
Keywords:
18F-Sodium Fluoride; 68Ga-1,4,7-triazacyclonone-1,4-diacetic acid; Breast cancer; Positron emission tomography
Authors: Vojtech Kubícek; Jakub Rudovský; Jan Kotek; Petr Hermann; Luce Vander Elst; Robert N Muller; Zvonimir I Kolar; Hubert Th Wolterbeek; Joop A Peters; Ivan Lukes Journal: J Am Chem Soc Date: 2005-11-30 Impact factor: 15.419
Authors: Konstantin P Zhernosekov; Dimitry V Filosofov; Richard P Baum; Peter Aschoff; Heiner Bihl; Anatoli A Razbash; Markus Jahn; Mark Jennewein; Frank Rösch Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Nina Pfannkuchen; Marian Meckel; Ralf Bergmann; Michael Bachmann; Chandrasekhar Bal; Mike Sathekge; Wolfgang Mohnike; Richard P Baum; Frank Rösch Journal: Pharmaceuticals (Basel) Date: 2017-05-18
Authors: Zarif Ashhar; Nor Azah Yusof; Fathinul Fikri Ahmad Saad; Siti Mariam Mohd Nor; Faruq Mohammad; Wan Hamirul Bahrin Wan Kamal; Muhammad Hishar Hassan; Hazlina Ahmad Hassali; Hamad A Al-Lohedan Journal: Molecules Date: 2020-06-09 Impact factor: 4.411
Authors: George P Keeling; Billie Sherin; Jana Kim; Belinda San Juan; Tilmann Grus; Thomas R Eykyn; Frank Rösch; Gareth E Smith; Philip J Blower; Samantha Y A Terry; Rafael T M de Rosales Journal: Bioconjug Chem Date: 2020-08-27 Impact factor: 4.774
Authors: Ambreen Khawar; Elisabeth Eppard; Frank Roesch; Hojjat Ahmadzadehfar; Stefan Kürpig; Michael Meisenheimer; Florian C Gaertner; Markus Essler; Ralph A Bundschuh Journal: EJNMMI Res Date: 2019-11-28 Impact factor: 3.138